LOSS OF HLA CLASS-I EXPRESSION IN PROSTATE-CANCER - IMPLICATIONS FOR IMMUNOTHERAPY

被引:150
作者
BLADES, RA
KEATING, PJ
MCWILLIAM, LJ
GEORGE, NJR
STERN, PL
机构
[1] UNIV S MANCHESTER HOSP,DEPT PATHOL SCI,MANCHESTER M20 8LR,LANCS,ENGLAND
[2] CHRISTIE HOSP NATL HLTH SERV TRUST,PATERSON INST CANC RES,DEPT IMMUNOL,CRC,MANCHESTER,LANCS,ENGLAND
关键词
D O I
10.1016/S0090-4295(99)80301-X
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives. There is currently no reliable predictor of the metastatic potential of apparently localized prostate cancer in an individual patient or satisfactory treatment for patients with advanced disease. One of the factors that may influence tumor progression is the cellular arm of the immune response, and central to this is the human leukocyte antigen (HLA) system, which acts to restrict T-cell recognition of potential tumor antigens, It has been reported in some cancers that down regulation of HLA class I expression by the tumor cells is associated with poor prognosis, In this report, HLA class I and II expression have been investigated in both benign and malignant prostate disease, first to define the extent of altered HLA expression and second to assess whether HLA expression may be related to disease progression. Methods. HLA expression was assessed by immunohistochemistry utilizing a set of monoclonal antibodies that recognize both monomorphic determinants and the commoner HLA class I allelic products. Results. in contrast to the normal HLA class I expression of the benign tissue, complete loss of HLA class I expression occurred in 34% of primary prostate cancers and 80% of lymph node metastases. When individual allelic expression was assessed, the minimum estimate of down regulation was 85% in the primary prostate cancers and 100% of the metastases. Conclusions. This investigation has demonstrated a higher rate of HLA class I loss than has been reported in other tumors and would suggest that the immune system may have an important role in the progression of prostate cancer, as well as having implications for the design and success of immunotherapy regimens in advanced disease.
引用
收藏
页码:681 / 686
页数:6
相关论文
共 50 条
[41]   ABSENCE OF HLA CLASS-I EXPRESSION IN REED-STERNBERG CELLS [J].
POPPEMA, S ;
VISSER, L ;
HEPPERLE, B .
LABORATORY INVESTIGATION, 1994, 70 (01) :A118-A118
[42]   Loss of heterozygosity is a major mechanism for loss of HLA class I expression in human gastric cancer [J].
Zhang, J ;
Shen, Y ;
Wang, X ;
Ye, Q ;
Miao, F ;
Xie, W .
TISSUE ANTIGENS, 2005, 66 (05) :599-600
[43]   "Hard" and "soft" lesions underlying the HLA Class I alterations in cancer cells: implications for immunotherapy [J].
Garrido, Federico ;
Cabrera, Teresa ;
Aptsiauri, Natalia .
INTERNATIONAL JOURNAL OF CANCER, 2010, 127 (02) :249-256
[44]   HUMAN CYTOMEGALOVIRUS DOWN-REGULATES HLA CLASS-I EXPRESSION BY REDUCING THE STABILITY OF CLASS-I H-CHAINS [J].
BEERSMA, MFC ;
BIJLMAKERS, MJE ;
PLOEGH, HL .
JOURNAL OF IMMUNOLOGY, 1993, 151 (09) :4455-4464
[45]   INTERACTIONS BETWEEN PEPTIDE AND CLASS-I MHC - IMPLICATIONS FOR IMMUNOTHERAPY IN RHEUMATIC DISEASE [J].
MOOTS, RJ ;
YOUNG, SP ;
STROMINGER, J ;
FRELINGER, JA ;
BACON, PA ;
MCMICHAEL, AJ .
BRITISH JOURNAL OF RHEUMATOLOGY, 1993, 32 :24-24
[46]   INTERACTIONS BETWEEN PEPTIDE AND CLASS-I MHC - IMPLICATIONS FOR IMMUNOTHERAPY IN RHEUMATIC DISEASE [J].
MOOTS, RJ ;
YOUNG, SP ;
STROMINGER, J ;
FRELINGER, JA ;
BACON, PA ;
MCMICHAEL, AJ .
ARTHRITIS AND RHEUMATISM, 1993, 36 (09) :S148-S148
[47]   EFFECT OF AN ANTI-HLA CLASS-I MONOCLONAL-ANTIBODY ON THE ANTIGENIC AND TRANSCRIPTIONAL EXPRESSION OF HLA CLASS-I GENES IN U937 CELLS [J].
GUILLAUDEUX, T ;
GAUDIN, A ;
COLLET, B ;
FAUCHET, R ;
TOUJAS, L .
TISSUE ANTIGENS, 1992, 40 (04) :159-164
[48]   Relationship between loss of heterozygosity of HLA-A gene and HLA class I expression in gastric cancer [J].
Yoshii, Mami ;
Tanaka, Hiroaki ;
Sakurai, Katsunobu ;
Nagahara, Hisashi ;
Kimura, Kenjiro ;
Amano, Ryosuke ;
Noda, Eiji ;
Kubo, Naoshi ;
Muguruma, Kazuya ;
Yamada, Nobuya ;
Yashiro, Masakazu ;
Maeda, Kiyoshi ;
Sawada, Tetsuji ;
Ohira, Masaichi ;
Ishikawa, Tetsuro ;
Hirakawa, Kosei .
CANCER RESEARCH, 2012, 72
[49]   HLA CLASS-I polymorphism and susceptibility of Iranian women with breast cancer [J].
Ghaderi, A ;
Razmkhah, M ;
Talei, A ;
Doroudchi, M ;
Gharesi-Fard, B .
TISSUE ANTIGENS, 2004, 64 (04) :423-423
[50]   MHC Class-I Loss and Cancer Immune Escape Introduction [J].
Garrido, Federico .
MHC CLASS-I LOSS AND CANCER IMMUNE ESCAPE, 2019, 1151 :1-14